Abstract 1687
Background
Although Brazilian publications on BRCA mutations predisposing to breast/ovarian cancer have increased in the last five years, the genetic Background of this population is still underrepresented. Mostly, screening has been performed in patients from south-southeast states who met the NCCN guidelines. We present a cohort of breast/ovarian cancer patients, in a private laboratory with a wide market capillarity, where a subset of patients without strict criteria may have access to the test on medical request.
Methods
A total of 1,284 consecutive patients were referred for molecular screening to a private laboratory between January 2017-March 2019. Next-generation sequencing and multiplex ligation-dependent probe amplification (MLPA) for BRCA1/2 genes were performed for all patients, except for 15 that were evaluated only by MLPA. Bioinformatic tools with specific algorithms for variant calling and annotation were employed.
Results
Pathogenic germline variants were identified in 12% (n = 156) of patients: 61% in BRCA1 and 39% in BRCA2. To our knowledge, 25 BRCA2 and 17 BRCA1 germline mutations have not been previously described in Brazilian reports. Frameshift and nonsense alterations were the most prevalent types (52% and 22%, respectively). While sixty non-recurring mutations were identified, 31 in BRCA1 and 29 in BRCA2, eleven pathogenic variants were detected 3 or more times, 7 BRCA1 and 4 BRCA2. In agreement with previous reports, c.5266dupC, c.3331_3334delCAAG (BRCA1) and c.2808_2811delACAA (BRCA2) were the most frequent variants. One large rearrangement (deletion of exons 15-16) and the Portuguese founder Alu insertion, c.156_157insAlu, both in BRCA2, were also detected. Additionally, three BRCA1 (c.5074 + 1delG; c.131_132delGC; c. 4414delC) and five BRCA2 (c.6407T>G, c.3659dupA, c.3601_3602delinsT, c.8682delA; c.4329delT) novel mutations were observed.
Conclusions
Our results confirm the reported molecular heterogeneity of Brazilian patients, highlighting the identification of 8 germline pathogenic variants not yet described in BRCA 1/2 reference databases. The detected mutations were associated to a vast array of ethnicities, confirming the admixture of Brazilian population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2860 - Prognostic value of metabolic response assessed by 18FDG-PET after induction chemotherapy and after chemoradiotherapy (CRT) in localized esophageal squamous cell carcinoma (ESCC) patients (pts) receiving definite CRT (dCRT)
Presenter: Yeonghak Bang
Session: Poster Display session 2
Resources:
Abstract
3881 - Comprehensive genomic profiling of early-stage esophageal squamous cell carcinoma
Presenter: Jing Zuo
Session: Poster Display session 2
Resources:
Abstract
3944 - A novel nomogram and risk classification system predicting radiation pneumonitis in patients with esophageal cancer receiving radiotherapy
Presenter: Lu Wang
Session: Poster Display session 2
Resources:
Abstract
1956 - Drinking alcohol, smoking, multiple dysplastic lesions and the risk of field cancerization of squamous cell carcinoma in the esophagus and head and neck region
Presenter: Chikatoshi Katada
Session: Poster Display session 2
Resources:
Abstract
2144 - Neoadjuvant chemotherapy can eliminate the negative impact of postoperative infectious complications on recurrence in patients with esophageal cancer
Presenter: Kazuki Kano
Session: Poster Display session 2
Resources:
Abstract
2403 - Comparison of chemoradiotherapy (CRT) followed by consolidation with cisplatin and 5-fluorouracil (CF) versus definitive CRT with carboplatin and paclitaxel (CP) in esophageal cancer
Presenter: Marcelle Cesca
Session: Poster Display session 2
Resources:
Abstract
3247 - Paclitaxel in Combination with Cisplatin and 5-fluorouracil(TPF) Induction Chemotherapy for Locally Advanced Borderline-resectable Esophageal Squamous cell Carcinoma: A Phase II Clinical Trial
Presenter: Yuhong Li
Session: Poster Display session 2
Resources:
Abstract
4293 - Prognosis of esophageal squamous cell carcinoma based on local immunity evaluation
Presenter: Elena Zlatnik
Session: Poster Display session 2
Resources:
Abstract
5419 - Impact of Sarcopenia and adiposity in survival of metastatic esophageal cancer (MEC)
Presenter: Aline Fares
Session: Poster Display session 2
Resources:
Abstract
2083 - PALAESTRA - A phase II trial with short-course radiotherapy followed by chemotherapy as palliative treatment in esophageal adenocarcinoma
Presenter: David Borg
Session: Poster Display session 2
Resources:
Abstract